Research Article

Prevalence and Risk Factors of Delayed Sputum Conversion among Patients Treated for Smear Positive PTB in Northwestern Rural Tanzania: A Retrospective Cohort Study

Daniel W. Gunda,1 Igembe Nkandala,1 Godfrey A. Kavishe,1 Semvua B. Kilonzo,1 Rodrick Kabangila,1 and Bonaventura C. Mpondo2

1Department of Medicine, Weill Bugando School of Medicine, P.O. Box 1464, Mwanza, Tanzania
2Department of Medicine, College of Health Sciences, University of Dodoma, P.O. Box 395, Dodoma, Tanzania

Correspondence should be addressed to Daniel W. Gunda; daniel_rev2002@yahoo.com

Received 18 April 2017; Accepted 21 May 2017; Published 11 June 2017

Academic Editor: Jean-Paul J. Gonzalez

Copyright © 2017 Daniel W. Gunda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Smear positive TB carries high morbidity and mortality. The TB treatment aims at sputum conversion by two months of antituberculous. Patients who delay sputum conversion remain potentially infectious, with risk of treatment failure, drug resistance, and mortality. Little is known about the magnitude of this problem in our setting. This study was designed to determine the prevalence and risk factors of delayed sputum conversion in northwestern rural part of Tanzania.

Methods. This was a retrospective cohort study involving smear positive TB patients at Sengerema DDH in 2015. Demographic data, HIV status, and sputum results at TB diagnosis and on TB treatment were collected and analyzed using STATA 11.

Results. In total, 156 patients were studied. Males were 97 (62%); the median age was 39 [30–51] years. Fifty-five (35.3%) patients were HIV coinfected and 13 (8.3%) patients had delayed sputum conversion which was strongly associated with male gender (OR = 8.2, \( p = 0.046 \)), age >50 years (OR = 6.7, \( p = 0.003 \)), and AFB 3+ (OR = 8.1, \( p = 0.008 \)).

Conclusions. Delayed sputum conversion is prevalent in this study. These patients can potentially fail on treatment, develop drug resistance, and continue spreading TB. Strategies to reduce the rate of delayed sputum conversion could also reduce these potential unfavorable outcomes.

1. Introduction

Tuberculosis (TB) is the oldest infectious disease that is still a global problem causing significantly high morbidity and mortality. It is estimated that about a third of the world’s population is infected with TB organism [1]. In 2015, there were more than 9.6 million people newly diagnosed with TB globally with a mortality of about 1.5 million people [2]. While it is estimated that about 80% of all TB cases occur in the 22 highest-burden countries [3], sub-Saharan Africa harbors about 70% of the words burden of TB [2]. In sub-Saharan Africa, more than 4 million people are estimated to suffer from active tuberculosis resulting in an estimated 650,000 deaths every year [4]. Tanzania is one of the 30 countries labeled as high burden countries with a total TB incidence of 164,000 people and prevalence of 275 per 100000 population [5]. A highest burden of TB is reported among densely populated regions with Dar es Salaam having the highest notification of 21.9% followed by Mwanza (9.3%), Shinyanga (6.4%), and Mbeya (6.0%) [6].

The diagnosis of TB is commonly made through sputum smear examination with smear positive patients being the most infectious ones [7] capable of infecting up to 15 people a year. Early diagnosis and prompt treatment initiation of smear positive patients are an important strategy with a goal line of sputum conversion at two months of intensive phase of potent antituberculous [8]. While sputum conversion at the end of the intensive phase is regarded as an important predictor of treatment success, a significant proportion of patients on antituberculous remain positive at the end of intensive phase with some places reporting a prevalence that is in excess of 25% [9]. These patients are
2. Materials and Methods

This was a cross-sectional clinic based cohort study done at Sengerema Designated District Hospital (DDH) between August 2016 and March 2017. The study involved all smear positive TB patients who were diagnosed and initiated treatment for TB between January and December 2015 and subsequently followed up at Sengerema DDH. Sengerema DDH is one of the district level hospitals in Mwanza region situated in the western part of Lake Victoria. It serves a catchment population of about 700,000 people with a capacity of around 300 beds. Sengerema DDH runs both in- and outpatients’ activities on daily basis serving between 200 and 300 patients a day. TB unit serves as part and parcel of the daily outpatient department seeing between 200 and 300 TB patients a year. Patients suspected of having TB from inpatient and outpatient departments get referred to TB unit for further diagnostic work-up. The diagnosis and treatment of TB were done according to Tanzanian TB and Leprosy guideline with sputum examination for AFB being carried on routine basis to categorize TB patients as smear positive [11]. Patients were additionally tested for HIV before commencement of antituberculous drugs. All patients received standard treatment for TB under DOTS as per reported guideline. Follow-up sputum examination was done as routine at 2 months of anti-TB and or monthly thereafter for nonsputum converters.

A TB registry was used to identify patients and their registration number was used to trace their files. The files were then reviewed by the study team to extract the information of research interest. The information regarding age, sex, address, HIV status, date of TB diagnosis, sputum smear results and density at diagnosis, follow-up sputum smear results, and time was recorded with a special tool. The data were double-entered and cleaned using Epi data version 3.1 and STATA version 11 (Stata Corp LP, College Station, TX) was used for analysis. All continuous variables were summarized as medians with interquartile range while the categorical variables were expressed as proportions with percentages. In this study, patients who had their follow-up sputum positive after intensive phase were coded as having delayed sputum conversion as used in other studies [9, 12]. The proportion of patients with delayed sputum conversion was calculated and logistic regression model was performed to determine the odds ratio and 95% CI to find out the degree of association between the outcome of interest and its potential risk factors. In all our calculations, any risk factor had a significant statistical association if the \( p \) value was <0.05.

2.1. Ethical Consideration. The permission to conduct and publish the information from this study was sought from the Bugando Medical Centre/Catholic University of Health and Allied Sciences (BMC/CUHAS) joint ethical and research committee and Sengerema DDH administration. The files were handled by researchers alone; the patients’ identifiers were not included to maintain confidentiality.

3. Results

3.1. The General Characteristics of the Study Participants. In total, 156 patients were treated for smear positive TB during the study period. Most of participants were male (97) (62.0%) with a male to female ratio of 1.64:1 and with a median age of 39 [30–51] years. More than one-third (55) (35.26%) of the study participants were HIV coinfected. The median TB bacilli density was 2 [2–3] (Table 1). Figure 1 summarizes the distribution of smear density at initiation of antituberculous drugs.

3.2. Prevalence and Risk Factors of Delayed Sputum Conversion. In this study, a total of 143 (91.7%) patients had smear conversion within the first two months of potent antituberculous treatment, while 13 (8.3%) had delayed sputum conversion (Table 1). More details on sputum conversion by months on anti-TB are given in Figure 2. The odds of having delayed sputum conversion were strongly associated with a male gender (OR = 8.2, \( p = 0.046 \)), age older than 50 years (OR = 6.7, \( p = 0.003 \)), and Acid Fast Bacilli density of 3+ (OR = 8.1, \( p = 0.008 \)). HIV coinfection was not significantly associated with delayed sputum conversion (Table 2).
### Table 2: Factors associated with delayed sputum smear conversion among 156 study participants treated with potent anti-TB medications.

| Variables               | Delayed smear conversion | OR (95% CI) | p value |
|-------------------------|--------------------------|-------------|---------|
|                         | No (n = 143)             | Yes (n = 13) |         |
| **Sex**                 |                          |             |         |
| Male                    | 85 (59.4)                | 12 (92.3)   | 8.2 [1.0–64.7] | 0.046 |
| Female                  | 58 (40.6)                | 01 (7.7)    |         |         |
| **Age**                 |                          |             |         |
| ≥50 years               | 36 (25.2)                | 09 (69.2)   | 6.7 [1.9–23.0] | 0.003 |
| <50 years               | 107 (74.8)               | 04 (30.8)   |         |         |
| **Resides in SGM**      |                          |             |         |
| Yes                     | 17 (11.9)                | 01 (7.7)    |         |         |
| No                      | 126 (88.1)               | 12 (92.3)   | 0.6 [0.1–5.0] | 0.653 |
| **HIV status**          |                          |             |         |
| Positive                | 50 (34.9)                | 05 (38.5)   |         |         |
| Negative                | 93 (65.1)                | 08 (61.5)   | 1.2 [0.4–3.7] | 0.801 |
| **Median AFB+**         |                          |             |         |
| 3 [3-3]                 | 2 [2-3]                  | 6.5 [1.5–27.3] | 0.011 |
| **Smear bacilli density**|                        |             |         |
| AFB 1+                  | 26 (18.2)                | 00 (00.0)   | —         | —         |
| AFB 2+                  | 59 (41.3)                | 02 (15.4)   | 0.3 [0.1–1.2] | 0.086 |
| AFB 3+                  | 58 (40.5)                | 11 (84.6)   | 8.1 [1.7–37.7] | 0.008 |

AFB: Acid Fast Bacilli; HIV: human immunodeficiency virus; CI: confidence interval; SGM: Sengerema.

### 4. Discussion

The objective of this study was to determine the prevalence and assess the risk factor of delayed sputum conversion among adult patients treated for smear positive TB in rural northwestern Tanzania. In this study, it was found that 13 (8.33%) had delayed sputum conversion beyond 2 months of intensive phase.

Our findings are comparable to findings from several other studies across the world with a varying rate of delayed sputum conversion. The prevalence of delayed sputum conversion at 2 months in the index study is similar to a prevalence of 8.1% reported from Ghana in 2015 by Acquah [13] and also similar to a prevalence 9.0% reported much earlier from India in 2006 [14] representing comparable rates of sputum conversion rates of 91.9% and 91%, respectively, at the end of intensive phase. On the other hand, slightly smaller prevalence of 7.3% of delayed sputum conversion at 2 months was reported recently from Cameroon [12]. However a much higher rate of non-sputum conversion of 25.4% was reported previously from Portugal in 2012 [9].

Several factors were investigated for their association with the odds of having delayed sputum conversion. These factors which could independently increase the risk of delayed sputum conversion include male gender, older age than 50 years, and AFB density of 3+. These findings are in agreement with those reported in Portugal in 2012. In this study, male patients were 10.8 times more likely to have delayed sputum conversion, while patients who were older than 50 years and those who had smear grade of 3+ had 4.4 and 11.7 times higher risk of delayed sputum conversions, respectively [9].
Similarly, Tiwari and colleagues indicated that the risk of smear nonconversion was increased among those with age older than 40 years (OR = 2.7, \( p = 0.003 \)), and pretreatment bacillary load of 3+ on sputum smears (OR = 1.9, \( p = 0.037 \)) delayed sputum conversion in addition to having a higher rate of treatment failure which tends to increase with bacilli density in sputum [15]. In their study of gender differences in distribution of TB, Balasubramanian et al. found that male patients were frequently found to have treatment failure associated with taking medications irregularly as compared to women [16] which could also explain the increased risk of delayed sputum conversion among male patients. On the other hand, preexisting comorbidities among older patients could be associated with a risk of reduced compliance to TB medications also increasing the risk of delayed sputum conversion as also suggested by other authors [17]. Other risk factors for delayed sputum conversions which were not assessed in this study include alcoholism [18], having cavities on a chest X-ray [19], and diabetes mellitus [20].

5. Conclusion
The proportion of TB patients with delayed sputum conversion on potent TB treatment is still high in northwestern rural Tanzania. Patients older than 50 years and those with high AFB density have the highest risk of delayed sputum conversion. These patients can potentially fail on treatment, develop drug resistance, and continue spreading TB. Strategies to reduce the rate of delayed sputum conversion could also reduce these potential unfavorable outcomes.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

References
[1] K. Lonnroth and M. Raviglione, “Global epidemiology of tuberculosis: prospects for control,” Seminars in Respiratory and Critical Care Medicine, vol. 29, no. 5, pp. 481–491, 2008.
[2] WHO/TB, Global tuberculosis report 2015. WHO/ tb publications, 2015.
[3] E. Keeler, M. D. Perkins, P. Small et al., “Reducing the global burden of tuberculosis: the contribution of improved diagnostics,” Nature, vol. 444, pp. 49–57, 2006.
[4] S. H. Kaufmann and S. K. Parida, “Tuberculosis in Africa: learning from pathogenesis for biomarker identification,” Cell Host and Microbe, vol. 4, no. 3, pp. 219–228, 2008.
[5] T. Qvist, F. Engsig, G. Kronborg et al., “Predictors of unsafe sex among HIV patients in Denmark: A population-based cohort study,” Scandinavian Journal of Infectious Diseases, vol. 43, no. 3, pp. 181–187, 2011.
[6] M. S. Paololetti, M. E. Fisher, K. R. Sreenivasan, and D. P. Lathrop, “Velocity statistics distinguish quantum turbulence from classical turbulence,” Physical Review Letters, vol. 101, no. 15, Article ID 154501, 2008.
[7] K. A. Septowitz, “How contagious is tuberculosis?” Clinical Infectious Diseases, vol. 23, no. 5, pp. 954–962, 1998.
[8] M. G¨uler, E. ¨Unsal, B. Dursun, ¨O. Aydin, and N. Capan, “Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis,” International Journal of Clinical Practice, vol. 61, no. 2, pp. 231–235, 2007.
[9] P. Caetano Mota, A. Carvalho, I. Valente, R. Braga, and R. Duarte, “Predictors of delayed sputum smear and culture conversion among a Portuguese population with pulmonary tuberculosis,” Revista Portuguesa de Pneumologia, vol. 18, no. 2, pp. 72–79, 2012.
[10] N. S. Shah, A. Wright, G. H. Bai et al., “Worldwide emergence of extensively drug-resistant tuberculosis,” Emerging Infectious Diseases, vol. 13, no. 3, pp. 380–387, 2007.
[11] MOHSW, “Manual of The National Tuberculosis And Leprosy Programme In Tanzania, 2006”.
[12] F. N. Djouma, M. Noubom, J. Atedjieu, and H. Donfack, “Delay in sputum smear conversion and outcomes of smear-positive tuberculosis patients: A retrospective cohort study in Bafoussam, Cameroon,” BMC Infectious Diseases, vol. 15, no. 1, article no. 139, 2015.
[13] Acquah, “Trends in sputum smear conversion among smear-positive pulmonary tuberculosis patients,” Journal of Medical and Biomedical Sciences, vol. 4, no. 1, pp. 24–33, 2015.
[14] M. Tahir, S. K. Sharma, D. S. Rohrberg, D. Gupta, U. B. Singh, and P. K. Sinha, "DOTS at a tertiary care center in northern India: successes, challenges and the next steps in tuberculosis control," Indian Journal of Medical Research, vol. 123, no. 5, pp. 702–706, 2006.

[15] S. Tiwari, A. Kumar, and S. K. Kapoor, "Relationship between sputum smear grading and smear conversion rate and treatment outcome in the patients of pulmonary tuberculosis undergoing dots—a prospective cohort study," Indian Journal of Tuberculosis, vol. 59, no. 3, pp. 135–140, 2012.

[16] R. Balasubramanian, R. Garg, T. Santha et al., "Gender disparities in tuberculosis: report from a rural DOTS programme in south India," International Journal of Tuberculosis and Lung Disease, vol. 8, no. 3, pp. 323–332, 2004.

[17] V. K. Arora, N. Singla, and R. Sarin, "Profile of geriatric patients under DOTS in Revised National Tuberculosis Control Programme," The Indian Journal of Chest Diseases & Allied Sciences, vol. 45, no. 4, pp. 231–235, 2003.

[18] P.G.Gopi, V.Chandrasekaran, R.Subramaniet al., "Association of conversion cure with initial smear grading among new smear positive pulmonary tuberculosis patients treated with Category I regimen," Indian Journal of Medical Research, vol. 123, no. 6, pp. 807–814, 2006.

[19] J.-Y. Wang, L.-N. Lee, C.-J. Yu, Y.-J. Chien, and P.-C. Yang, "Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis," Respiratory Medicine, vol. 14, no. 7, pp. 1012–1019, 2009.

[20] S. Pajankar, R. Khandekar, M. A. Al Amri, and M. R. Al Lawati, "Factors influencing sputum smear conversion at one and two months of tuberculosis treatment," Oman Medical Journal, vol. 23, no. 4, pp. 263–268, 2008.

[21] J. A. Caminero et al., "Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding," International Journal of Tuberculosis and Lung Disease, vol. 14, no. 4, pp. 382–390, 2010.

[22] E. W. Pefura-Yone, A. P. Kengne, and C. Kuaban, "Non-conversion of sputum culture among patients with smear positive pulmonary tuberculosis in Cameroon: a prospective cohort study," BMC Infectious Diseases, vol. 14, no. 1, article no. 138, 2014.

[23] G. B. Migliori, A. Matteelli, D. Cirillo, and M. Pai, "Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current standards and challenges," Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 19, no. 2, pp. 169–172, 2008.